A team reported an Adjustable RNA Information Manipulation (AIM) platform that uses a single‑strand deaminase to enable precise, site‑specific RNA editing, marking a step forward for transient nucleic acid therapeutics. Published in Nature Biotechnology, the work demonstrates controllable RNA base conversions with reduced bystander editing and tunable activity, offering a potential alternative to permanent DNA edits for applications where temporality and reversibility are desired. The study details biochemical optimization and cellular validation, positioning AIM as a candidate modality for diseases where transient modulation of RNA is preferable.